Raymond James Financial Services Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-18,000	Closed	-$27K	–	2850
2019 Q3	$27K	Sell	18,000 -425	-2%	-$993	﹤0.01%	2732
2019 Q2	$74K	Sell	18,425 -200	-1%	-$815	﹤0.01%	2712
2019 Q1	$80K	Buy	18,625 +25	+0.1%	+$116	﹤0.01%	2666
2018 Q4	$107K	Sell	18,600 -225	-1%	-$1.66K	﹤0.01%	2388
2018 Q3	$255K	Sell	18,825 -13,126	-41%	-$138K	﹤0.01%	2375
2018 Q2	$379K	Buy	31,951 +13,151	+70%	+$164K	﹤0.01%	2069
2018 Q1	$211K	Sell	18,800 -200	-1%	-$1.75K	﹤0.01%	2222
2017 Q4	$127K	Hold	19,000	–	–	﹤0.01%	2348
2017 Q3	$156K	Sell	19,000 -1,300	-6%	-$8.12K	﹤0.01%	2332
2017 Q2	$91K	Sell	20,300 -1,527	-7%	-$7.98K	﹤0.01%	2353
2017 Q1	$120K	Buy	+21,827	New	+$95.5K	﹤0.01%	2238

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Raymond James Financial Services Advisors's ADAP Position: Q4 2019 in Review

Raymond James Financial Services Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2019, closing a stake of 18,000 shares — an estimated $27K sold.

Raymond James Financial Services Advisors first reported a position in ADAP in Q1 2017 and held it in 11 quarters. The position peaked at $379K in Q2 2018. 43 funds tracked by Wall St. Rank hold ADAP as of Q4 2019.

Raymond James Financial Services Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
Raymond James Financial Services Advisors sold 18,000 Adaptimmune Therapeutics shares in Q4 2019, an estimated $27K.
Raymond James Financial Services Advisors first reported a position in Adaptimmune Therapeutics in Q1 2017 and held it in 11 quarters.
Raymond James Financial Services Advisors's Adaptimmune Therapeutics position peaked at $379K in Q2 2018.
43 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.